What is HC Wainwright’s Estimate for AKBA FY2029 Earnings?

Akebia Therapeutics, Inc. (NASDAQ:AKBA) – Equities researchers at HC Wainwright issued their FY2029 EPS estimates for shares of Akebia Therapeutics in a note issued to investors on Tuesday, January 14th. HC Wainwright analyst E. Arce forecasts that the biopharmaceutical company will earn $2.17 per share for the year. HC Wainwright currently has a “Buy” rating and a $7.50 target price on the stock. The consensus estimate for Akebia Therapeutics’ current full-year earnings is ($0.24) per share.

Separately, StockNews.com cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday.

Akebia Therapeutics Stock Up 2.6 %

Shares of AKBA opened at $1.94 on Thursday. The stock has a market cap of $423.27 million, a P/E ratio of -8.43 and a beta of 0.72. The business’s 50 day moving average price is $1.90 and its 200-day moving average price is $1.56. Akebia Therapeutics has a 52 week low of $0.80 and a 52 week high of $2.48.

Akebia Therapeutics (NASDAQ:AKBA) last announced its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06). The business had revenue of $37.43 million for the quarter, compared to analyst estimates of $45.66 million. During the same quarter in the previous year, the business posted ($0.08) EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Wellington Management Group LLP purchased a new stake in shares of Akebia Therapeutics during the third quarter valued at approximately $534,000. BNP Paribas Financial Markets lifted its position in Akebia Therapeutics by 205.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 46,270 shares of the biopharmaceutical company’s stock valued at $61,000 after acquiring an additional 31,137 shares in the last quarter. XTX Topco Ltd bought a new position in Akebia Therapeutics in the 3rd quarter valued at approximately $58,000. Bank of New York Mellon Corp boosted its stake in Akebia Therapeutics by 3,122.2% during the 2nd quarter. Bank of New York Mellon Corp now owns 604,551 shares of the biopharmaceutical company’s stock valued at $617,000 after purchasing an additional 585,789 shares during the last quarter. Finally, State Street Corp increased its holdings in shares of Akebia Therapeutics by 24.9% in the 3rd quarter. State Street Corp now owns 3,430,527 shares of the biopharmaceutical company’s stock worth $4,528,000 after purchasing an additional 683,287 shares in the last quarter. 33.92% of the stock is owned by hedge funds and other institutional investors.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company’s lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.